CN103025307A - 菊苣酸及衍生物用于调节皮肤色素沉着的用途 - Google Patents
菊苣酸及衍生物用于调节皮肤色素沉着的用途 Download PDFInfo
- Publication number
- CN103025307A CN103025307A CN2011800306929A CN201180030692A CN103025307A CN 103025307 A CN103025307 A CN 103025307A CN 2011800306929 A CN2011800306929 A CN 2011800306929A CN 201180030692 A CN201180030692 A CN 201180030692A CN 103025307 A CN103025307 A CN 103025307A
- Authority
- CN
- China
- Prior art keywords
- skin
- extract
- aforementioned
- described application
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 title claims abstract description 38
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 title claims abstract description 38
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 title claims abstract description 38
- 229930016920 cichoric acid Natural products 0.000 title claims abstract description 38
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 title claims abstract description 38
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 title claims abstract description 38
- 208000012641 Pigmentation disease Diseases 0.000 title claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 title 1
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 56
- 239000000284 extract Substances 0.000 claims description 46
- 241001597008 Nomeidae Species 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 15
- 230000003213 activating effect Effects 0.000 claims description 13
- 230000008591 skin barrier function Effects 0.000 claims description 7
- 208000003351 Melanosis Diseases 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002087 whitening effect Effects 0.000 claims description 6
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 5
- 230000003796 beauty Effects 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 239000006041 probiotic Substances 0.000 claims description 4
- 230000000529 probiotic effect Effects 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- 208000031019 skin pigmentation disease Diseases 0.000 claims description 4
- 206010008570 Chloasma Diseases 0.000 claims description 3
- 201000011252 Phenylketonuria Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 241000219095 Vitis Species 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 201000009442 piebaldism Diseases 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 235000009392 Vitis Nutrition 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 230000002605 anti-dotal effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940126701 oral medication Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 238000003809 water extraction Methods 0.000 claims 2
- 241000723343 Cichorium Species 0.000 claims 1
- 208000006981 Skin Abnormalities Diseases 0.000 claims 1
- 235000020795 whole food diet Nutrition 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 208000000069 hyperpigmentation Diseases 0.000 abstract description 5
- 230000003810 hyperpigmentation Effects 0.000 abstract description 5
- 239000007854 depigmenting agent Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 39
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 230000008569 process Effects 0.000 description 11
- 239000005418 vegetable material Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000019612 pigmentation Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108010076039 Polyproteins Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005238 degreasing Methods 0.000 description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 4
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 4
- 229960004705 kojic acid Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005282 brightening Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108700034262 4-Nle-7-Phe-alpha- MSH Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- UAHFGYDRQSXQEB-LEBBXHLNSA-N afamelanotide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-LEBBXHLNSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- 0 CC(Cc(cc1)cc(*)c1O)C(OC(C1OC(C=Cc2ccc(*)c(*)c2)=*1)C(O)=O)=O Chemical compound CC(Cc(cc1)cc(*)c1O)C(OC(C1OC(C=Cc2ccc(*)c(*)c2)=*1)C(O)=O)=O 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006297 Origanum majorana Nutrition 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明总的涉及用于美容目的的食品补充剂领域。更具体地讲,本发明旨在提供一种包含菊苣酸和/或衍生物的成分,用于预防和/或治疗皮肤的过度色素沉着、皮肤色斑例如老人斑和特征在于色素异常的其它皮肤病症。本发明的目的还在于改善皮肤色调以及提供皮肤美白剂。
Description
本发明总的涉及用于美容目的的食品补充剂领域。更具体地讲,本发明旨在提供一种包含菊苣酸和/或衍生物的成分,用于预防和/或治疗皮肤的过度色素沉着、皮肤色斑例如老人斑和特征在于色素异常的其它皮肤病症。本发明的目的还在于改善皮肤色调以及提供皮肤美白或增白剂。
发明背景
皮肤颜色主要是由存在于皮肤中的一种棕色色素--黑色素的量和类型决定的。黑色素的量越少皮肤越白,量越多皮肤颜色越深。此外,皮肤的过度色素沉着也是由皮肤中黑色素的过度表达或积聚造成的。因此,黑色素产生所涉及的途径已经成为许多用来降低黑色素产生水平的抑制剂的靶点。在黑色素途径中所涉及的主要的酶之一是酪氨酸酶。
黑色素的合成是一个受激素控制的过程,包括由前体阿黑皮素原产生的促黑素細胞激素(MSH)和促肾上腺皮质激素(ACTH)肽。由UVB照射所引起的DNA损伤可以刺激该过程。
因此,长时间的日晒会引起皮肤中的许多生化反应,导致例如皮肤晒黑和晒成褐色。日晒的其它后果会随着时间而累积。这些变化可以引起老人斑的出现并产生不均匀的、斑驳的皮肤色调。不幸的是,目前在市场上可购买到的许多产品要么仅有很弱的效果,要么含有不稳定的活性成分,这些成分在掺入最终的配方中时会失去它们的效力。
在当今社会,非常希望能够改变皮肤中色素的表达量,以促进均匀或美白的肤色。许多人希望改变他们的肤色,以减少老人斑等,或者是为了纯粹的美容原因。
其结果是,开发有效组合物的尝试都集中在了抑制酪氨酸酶活性的物质上。例如,已提出将各种酪氨酸酶抑制剂例如氢醌、维生素C、半胱氨酸、曲酸、熊果苷和谷胱甘肽等用于局部组合物中。此外,也有人提出将多种皮肤病学组合物用于改善色素异常(例如在黄褐斑、雀斑、白癜风、斑驳病、苯丙酮尿症等中所观察到的那些)的面貌和/或用于美容目的。
此外,皮肤漂白组合物的使用也被广泛延伸。然而,它们或者破坏黑色素,或者是抑制其形成。许多这样的组合物含有苛性化学物质,例如过氧化物、酸或甲醛,或硫醇化的物质。不太苛性的疗法具有其它缺点。
有人提出使用局部类视色素和局部皮质甾类作为色素减轻剂,还有人提出了激光疗法和化学去皮法,但这些方法的缺点是无法获得所需的响应。
其它一些组合物提出在皮肤上使用天然物质,其中有些天然物质已经在亚洲或欧洲使用了数个世纪,用来漂白皮肤和皮肤区域,或用于增强白皙皮肤的美感。其中包括使用柠檬、橙、黄瓜、银杏、长豆角、玫瑰果、老鹳草、肉桂、马郁兰、迷迭香等。
为了对抗与异常色素有关的病症或者为了美白肤色,已提出使用各种当局部涂抹在皮肤上时能够降低酪氨酸酶活性并因此限制黑色素产生的化合物。不幸的是,目前可以采用的处置方法不能完全令人满意,特别是在经常伴随的副作用方面,例如某些局部活性剂的刺激性副作用。
因此,非常希望不存在现有技术中所记载的那些缺点的其它可替代的制剂。具体地讲,非常希望开发出用于通过口服途径施用的营养性美容组合物,其具有改善的稳定性和促进均匀肤色或美白肤色的效力。
此外,还需要对于治疗和/或预防皮肤色素沉着异常、特别是由于环境因素或衰老所引起的那些异常有效的活性剂。
本发明的目的满足了这些需求。
发明概述
本发明人可以通过提供含有至少一种包含菊苣酸和/或衍生物的成分的食品补充剂组合物实现该目的。
因此,本发明的第一个主题涉及有效量的至少一种包含菊苣酸和/或衍生物的成分作为活性剂用于治疗和/或预防皮肤色素沉着异常的美容应用。所述皮肤病症特别是那些由于年龄或环境(例如紫外线)因素引起的异常,例如老人斑。其还可以是在黄褐斑、雀斑、白癜风、斑驳病、苯丙酮尿症等中所观察到的那些。
本发明人发现,菊苣酸及衍生物可以有效抑制黑色素的形成(黑素生成),尽管事实上该提取物对酪氨酸酶的活性的抑制很弱或没有抑制。考虑到酪氨酸酶在黑素生成中的关键作用以及现有技术中的开发尝试都集中在对该酶的抑制上,该结果是令人惊奇并且出人意料的。
对于本发明的目的而言,术语“皮肤”是指面部或身体的皮肤。
对于本发明的目的而言,术语“有效量”是指足以获得预期效果的量。
对于本发明的目的而言,术语“预防”是指降低所考虑的异常/病症的迹象出现的危险性。
本发明还涉及上述成分作为活性剂用于治疗和/或预防皮肤色斑的美容应用。其结果是,肤色变得更亮更均匀,没有皮肤变色或干燥的区域。
本发明还涉及有效量的至少一种本发明的包含菊苣酸和/或衍生物的成分作为活性剂用于增白或美白皮肤色调的美容应用。
本发明人还发现,本发明的成分可以进一步改善皮肤含水量和/或皮肤屏障功能。
本发明的应用还包括至少一种包含菊苣酸和/或衍生物的成分与有效量的至少一种用于进一步改善皮肤含水量或皮肤老化的活性剂、特别是下述的那些活性剂的组合应用。
另一方面,本发明的主题涉及在个体中治疗和/或预防皮肤色斑以及与过度色素沉着有关的病症、特别是美学上的病症的方法、特别是美容方法,该方法包括至少一个向所述个体施用至少一种本发明的包含菊苣酸和/或衍生物的成分的步骤。
本发明的组合物可以口服给药。其优点是可以通过迅速并且相对无限制性的给药方式全身作用于整个皮肤的深层(真皮、下皮)。具体地讲,代谢物及其它活性营养物质通过血流的作用特别分布于皮肤基质内。口服给药还具有迅速和相对无限制性给药方式的优点。
发明详述
包含菊苣酸和/或衍生物的成分
菊苣酸是
菊苣酸的衍生物包括
R1、R2、R3和/或R4可以相同或彼此不同。
在一个实施方案中,R1、R2、R3和/或R4可以选自H;CH3;C1-C3-烷基;芳基,例如苯基、苄基、甲苯基、邻二甲苯基烷基;C1-C3-酰基;氨基酸;单糖、二糖或寡糖。寡糖含有2至9个单糖单元。R1、R2、R3和R4可以相同和/或可以彼此不同。
一种典型的菊苣酸衍生物是例如如下化合物:
包含菊苣酸和/或其衍生物的成分可以是包含菊苣酸和/或其衍生物的任何成分,其可以是天然的或是另外添加的形式,但优选天然的食品例如莴苣、菊苣、蒲公英、葡萄、葡萄皮渣;或其组合或提取物。
在一个优选的实施方案中,植物材料是菊苣或其提取物的形式。菊苣提取物可以从植物材料的任何适宜部分制得,包括,例如根、果肉等,或其组合。
用于本发明目的的适宜的菊苣提取物还可以是可购买到的提取物,例如Leroux MS55(可购自Leroux SAS,法国)。
在一个特别优选的本发明实施方案中,适宜的菊苣提取物可以通过本领域已知的任何方法制备,例如,通过蒸汽提取、溶剂提取、蒸馏、挤压或研磨来制备。
为了便于操作,植物材料优选是干燥并且是粉碎或粉末的形式。如下所述,加工过程使用干燥、粉碎的菊苣和/或其提取物。但是,应当理解,可以以任何适宜的形式使用任何适宜的植物材料并将其加入到本发明的产物中。
对提取物进行加工从而使其风味可以提高。例如,可以通过将植物加工成提取物来去除植物材料例如菊苣通常带有的苦味。还可以制备提取物以使最终的提取物产品中生物活性剂的量可以被理想地控制。
应当理解,可以以多种不同的适宜方式将植物材料加工成提取物。通常,将植物材料例如菊苣根碾碎、制成粉末或以任何适宜的形式提供。然后可以将植物材料在多个不同的阶段进一步加工以生成产品提取物。在一个实施方案中,对植物材料进行脱脂工艺以生产由去除了脂肪的植物材料制得的提取物。脱脂工艺可以在任何适宜的脱脂加工条件下用任何适宜类型和数量的溶剂、包括例如己烷进行。
在一个实施方案中,由脱脂工艺制得的提取物可以进一步通过酸水解进行加工,以生产可以加入到本发明的营养组合物中的另一种类型的植物提取物。酸水解工艺可以在任何适宜的加工条件下使用任何适宜类型和数量的溶剂、包括例如乙酸乙酯进行。
在一个实施方案中,由脱脂工艺制得的提取物可以进一步通过溶剂提取工艺进行加工。溶剂提取可以在任何适宜的加工条件下在任何适宜量和类型的溶剂存在下进行。在一个实施方案中,溶剂包括甲醇("MeOH")和水以1:1的体积比混合的溶液。由溶剂提取工艺得到的溶液可以通过在适宜条件下蒸发溶剂进行进一步加工,以生产另一种提取物。或者,可将得到的溶液用吸附剂例如聚乙烯聚吡咯烷酮等处理,以捕获多酚。吸附剂处理可以在任何适宜的加工条件下进行。
产品中菊苣酸和/或其天然来源的量取决于许多因素,例如提取物的性质、植物的情况、待治疗的人或动物的年龄、状况和个头大小、产品准备施用的频率和/或待治疗或预防的皮肤病症或损伤的具体类型或所需的美容效果。
本发明人发现,本发明的菊苣或其提取物的效力通常是剂量依赖型的并且遵循剂量响应曲线。如果需要预防的是轻微的皮肤病症或损伤并且产品将频繁地使用,则非常少量的菊苣或其提取物就将足以获得所需的效果。如果需要治疗的是严重的皮肤色素异常,更大量的菊苣或其提取物将是更适宜的,尽管小的量也会产生效果。
通常,成分中富含菊苣酸和/或其衍生物是优选的。例如,成分和/或组合物中可以包含含量范围为干重的0.001-99.99重量%,优选干重的0.1-50重量%,最优选干重的0.1-10重量%的菊苣酸和/或其衍生物。成分和/或组合物可以包含含量范围为干重的0.001-99.99重量,优选干重的0.1-50重量%,最优选干重的0.1-10重量%的能够水解菊苣酸和/或其衍生物以生成酒石酸和/或咖啡酸的乳酸菌。
通常,在产品中包含含量范围为约0.1g/l至10g/l,优选0.5g/l至3g/l产品的菊苣或其提取物是优选的。如果产品的总量不能以升计,则优选在产品中包含含量范围为约0.1g/kg至10g/kg,优选0.5g/kg至3g/kg产品的菊苣或其提取物。优选在产品中包含每日剂量为0.01g-100g,优选0.25g-10g的菊苣或其提取物。
本发明的组合物可以是任何通常适用于所选择的施用方法的盖仑制剂形式。
口服组合物
本发明的组合物可以是任何通常适用于所选择的施用方法的盖仑制剂形式。根据所考虑的组合物类型,载体可以具有不同的性质。
具体地讲,菊苣或其提取物可以掺入任何形式的食品补充剂中。
例如,其可以存在于胶囊、明胶胶囊、软胶囊、片剂、糖包衣片剂、丸剂、糊剂或锭剂、口香糖或可饮用的溶液或乳液、糖浆或凝胶中。所述补充剂还可以包含甜味剂、稳定剂、抗氧剂、添加剂、矫味剂和/或着色剂。其配制通过用于生产糖包衣片剂、明胶胶囊、凝胶、控释水凝胶、乳剂、片剂或胶囊的常用方法来进行。
应用
本发明的产品可以通过例如减少黑色素的生成有效地用于治疗或预防皮肤色素沉着异常或在美容上用于美白肤色等。确实,菊苣酸及菊苣提取物显示出可以在体外减少黑色素的合成(实施例1,图1)。酪氨酸酶的生成也减少,但程度有限(图2),这表明黑色素的减少不是由于酪氨酸酶的抑制,而是由于作用于该酶的上游或下游的机制。
本发明的成分还对加固皮肤屏障以及皮肤保湿具有积极作用。
其结果是,色斑减少,肤色变得更亮更均匀,没有皮肤变色或干燥的区域。
因此,本发明的一个主题涉及有效量的至少一种包含菊苣酸和/或衍生物的成分作为活性剂用于治疗和/或预防皮肤色素沉着异常,特别是由于年龄或环境因素例如紫外线引起的异常的美容应用。
本发明还涉及有效量的至少一种包含菊苣酸和/或衍生物的成分作为活性剂用于增白或美白肤色的美容应用,这是亚洲人特别希望的。
本发明的应用还包括至少一种包含菊苣酸和/或衍生物的成分与有效量的至少一种用于改善皮肤含水量或皮肤老化的活性剂、特别是下述的那些活性剂的组合应用。
另一方面,本发明的主题涉及在个体中治疗和/或预防皮肤色斑以及与过度色素沉着有关的病症、特别是美学上的病症的方法、特别是美容方法,该方法包括至少一个向所述个体施用至少一种本发明的包含菊苣酸和/或衍生物的成分的步骤。
本发明的美容性治疗方法可以通过口服施用至少有效量的至少一种本发明的包含菊苣酸和/或衍生物的成分来进行。口服施用包括一次或分多次摄入以上所定义的口服组合物。
其可以包括单次应用。根据另一个实施方案,应用可以每天重复例如2至3次或更多,并且通常持续至少4周或是1至15周。
此外,为了补充或强化本发明所定义的成分的活性,还可以考虑任选的与口服或局部形式的组合治疗。
因此,本发明的包含菊苣或其提取物的组合物与任选地含有另一种活性成分、特别是益生微生物或其它死亡、活的或半活形式的益生菌或保湿剂或抗衰老剂的口服或局部组合物组合的局部或口服治疗可以被看作是药盒。在配制前,将成分按照本领域技术人员很容易确定的顺序和条件进行混合。
在配制前,将成分按照本领域技术人员很容易确定的顺序和条件进行混合。
从以下的实施例和附图中可以明显看出本发明的其它优点和特征。因此,以下实施例用于以非限制性的方式说明本发明的领域。除非另有说明,在这些实施例中的百分比是重量百分比,以“…至…”写出的数值范围包括具体指明的上限和下限。
附图
图1:与对照相比,用菊苣酸或菊苣提取物预处理的鼠黑素细胞的黑色素生成(阳性/阴性)。
图2:与对照相比,用菊苣酸或菊苣提取物预处理的鼠黑素细胞的酪氨酸酶生成(阳性/阴性)。
图3:与对照相比,用菊苣酸或菊苣提取物预处理的人原代表皮角质形成细胞的丝聚蛋白合成(阳性/阴性)。
实施例
实施例1:菊苣酸和菊苣提取物对皮肤色素沉着的影响
为了评估成分对皮肤脱色或促进色素沉着的潜在有益作用,我们用鼠黑素细胞的2D培养物(B16)进行了2项试验:1-评估黑色素生成和2-评估酪氨酸酶生成。
1.细胞培养条件
将B16细胞在含有1g/L葡萄糖、不含酚红、补充有10%胎牛血清的DMEM中在增湿培养室中在37°C、含5%CO2的条件下培养。
2.由B16鼠黑素细胞系生成的黑色素
将细胞与选定的成分或试验参照物(曲酸,400μg/mL)一起在存在或不存在MSH的类似物NDP-MSH的条件下保温72小时。黑色素的总量(细胞外和细胞内的)通过在405nm下测定各样品与黑色素标准品相比在存在或不存在NDP-MSH条件下的光密度来评估。
3.由B16鼠黑素细胞系生成的酪氨酸酶
将细胞与选定的成分或试验参照物(曲酸,400μg/mL)一起保温48小时。通过免疫标记法评估酪氨酸酶的生成。
成分
结果
结果以相对于对照的百分比表示。正如所预期的,试验参照物(曲酸)引起了黑色素生成的减少。图1显示了用选定的成分处理72小时的B16黑素细胞所生成的黑色素。
菊苣提取物MS-55显示在体外使黑色素生成减少了60%(图1),而菊苣酸使黑色素生成减少了90%。这些成分也使酪氨酸酶的生成减少,但程度有限(对MS-55和菊苣酸而言均低于20%,图2),这表明黑色素的减少不是由于酪氨酸酶的抑制,而是由于作用于该酶的上游或下游的机制。
实施例2:菊苣酸和菊苣提取物对皮肤屏障功能和皮肤含水量的影响
使用人原代表皮角质形成细胞的2D培养物,通过评估丝聚蛋白的合成来评估实施例1的提取物对皮肤屏障功能和皮肤含水量的潜在有益作用。
细胞培养条件
将人表皮角质形成细胞在限制性角质形成细胞无血清培养基中在增湿培养室中在37°C、含5%CO2的条件下培养。
由人表皮角质形成细胞合成丝聚蛋白
将细胞与选定的成分或试验参照物(CaCl2,1.5mM)一起保温144小时。通过免疫标记法评估丝聚蛋白的生成。
结果
结果如图3所示。将细胞用菊苣提取物MS-55、MS-70和菊苣酸预处理导致丝聚蛋白的增加,这表明这些提取物可加固皮肤屏障(图3)。较强的皮肤屏障可以更好地保护机体免受环境和病原体的攻击。其还限制了通过表皮的水分丢失,从而确保了适宜的皮肤含水量。
实施例3:粉棒(Powder stick)
成分 | 量 |
活性成分 | |
菊苣提取物MS-55 | 8g |
赋形剂 | |
麦芽糖糊精 | 适量至30g |
黄原胶 | 0.8mg |
苯甲酸钠 | 0.2mg |
可以每天食用一条粉棒。
Claims (14)
1.有效量的至少一种包含菊苣酸和/或衍生物的成分作为活性剂在制备用于治疗和/或预防皮肤色素异常和/或皮肤色斑的口服食品补充剂中的美容应用。
2.前述权利要求之一所述的应用,其特征在于所述皮肤异常是在黄褐斑、雀斑、白癜风、斑驳病、苯丙酮尿症等中所观察到的那些和/或老人斑。
3.前述权利要求之一所述的应用,用于改善皮肤色调和/或肤色。
4.有效量的至少一种包含菊苣酸和/或衍生物的成分作为活性剂在制备用于美白或增白皮肤色调的口服食品补充剂中的美容应用。
5.前述权利要求之一所述的应用,其中的组合物还可改善皮肤含水量。
6.前述权利要求之一所述的应用,其中的组合物还可改善皮肤屏障功能。
7.前述权利要求之一所述的应用,其中的提取物可以通过溶剂提取从菊苣植物材料获得,特别是通过水提取或醇/水提取,例如通过乙醇/水提取。
8.前述权利要求之一所述的应用,其中包含菊苣酸的成分是一种天然食品例如莴苣、菊苣、蒲公英、葡萄、葡萄皮渣;或其组合或提取物。
9.前述权利要求之一所述的应用,其中产品中菊苣或其提取物的含量在约0.1g/l至10g/l的范围内,优选在0.5g/l至3g/l的范围内。
10.前述权利要求之一所述的应用,其中产品含有日剂量为0.01g-100g,优选0.25g-10g的菊苣或其提取物。
11.前述权利要求之一所述的应用,其中的组合物还含有至少一种食品级的死亡、活的或半活形式的微生物,特别是益生菌。
12.前述权利要求之一所述的应用,与有效量的至少一种用于改善皮肤含水量或皮肤老化的活性剂组合应用。
13.用于治疗和/或预防皮肤色素异常和/或皮肤色斑的美容性治疗方法,包括至少一个向个体施用有效量的菊苣或其提取物的步骤。
14.用于治疗和/或预防皮肤色素异常和/或皮肤色斑的药盒,包括用含有菊苣或提取物的食品补充剂的口服治疗,与任选地含有死亡、活的或半活形式的益生菌微生物或保湿剂或抗衰老剂的口服或局部组合物的组合。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10167866 | 2010-06-30 | ||
EP10167866.2 | 2010-06-30 | ||
PCT/EP2011/060765 WO2012000960A1 (en) | 2010-06-30 | 2011-06-28 | Use of chicoric acid and derivatives for regulating skin pigmentation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103025307A true CN103025307A (zh) | 2013-04-03 |
CN103025307B CN103025307B (zh) | 2017-03-29 |
Family
ID=43218507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180030927.4A Expired - Fee Related CN102958501B (zh) | 2010-06-30 | 2011-06-28 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
CN201180030692.9A Expired - Fee Related CN103025307B (zh) | 2010-06-30 | 2011-06-28 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180030927.4A Expired - Fee Related CN102958501B (zh) | 2010-06-30 | 2011-06-28 | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9491962B2 (zh) |
EP (1) | EP2588071B1 (zh) |
JP (1) | JP2013530995A (zh) |
KR (1) | KR20130097090A (zh) |
CN (2) | CN102958501B (zh) |
BR (1) | BR112012032877B1 (zh) |
CA (1) | CA2803522C (zh) |
CL (1) | CL2012003624A1 (zh) |
ES (1) | ES2741424T3 (zh) |
MX (1) | MX2012015235A (zh) |
RU (1) | RU2012155852A (zh) |
SG (2) | SG10201505158UA (zh) |
WO (2) | WO2012000954A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666518A (zh) * | 2013-11-27 | 2015-06-03 | 瑞帝安有限公司 | 含有菊苣及枸桔的提取物的皮肤屏障强化用组合物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2766009B1 (en) * | 2011-10-11 | 2019-10-09 | ELC Management LLC | Method and compositions for treating skin |
EP2848286A1 (en) * | 2013-09-12 | 2015-03-18 | DSM IP Assets B.V. | Cosmetic composition comprising chicoric acid |
FR3017510B1 (fr) | 2014-02-19 | 2017-04-21 | Inst Nat De La Rech Agronomique - Inra | Composition phytosanitaire |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
JP2019510036A (ja) | 2016-03-31 | 2019-04-11 | ゴジョ・インダストリーズ・インコーポレイテッド | プロバイオティクス/プレバイオティクス有効成分を含む清浄剤組成物 |
AU2017365019A1 (en) | 2016-11-23 | 2019-07-11 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
KR102249072B1 (ko) * | 2019-07-11 | 2021-05-06 | 인하대학교 산학협력단 | 치커리 추출물을 유효성분으로 함유하는 백반증 또는 백모증의 예방 또는 치료용 약학적 조성물 |
CN111387505B (zh) * | 2020-04-21 | 2023-04-07 | 中国农业科学院都市农业研究所 | 一种对黑色素合成抑制的生菜提取物及生菜配套栽培方法 |
TW202346276A (zh) * | 2022-01-27 | 2023-12-01 | 日商田邊三菱製藥股份有限公司 | 新穎之b0at1抑制劑 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040170581A1 (en) * | 2001-05-21 | 2004-09-02 | Florence Henry | Cosmetic agents |
JP2005194246A (ja) * | 2004-01-09 | 2005-07-21 | Ichimaru Pharcos Co Ltd | NF−κB活性化抑制剤 |
CN102333455A (zh) * | 2009-01-27 | 2012-01-25 | 雀巢产品技术援助有限公司 | 包含菊苣酸和/或其衍生物的组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2591073B1 (fr) * | 1985-12-10 | 1988-02-19 | Leroux Sarl Chicoree | Boisson a base de chicoree et procede de preparation de ladite boisson |
FR2653336B1 (fr) * | 1989-10-20 | 1994-04-08 | Oreal | Composition pharmaceutique et cosmetiques depigmentantes a base d'acide cafeique. |
JP3140876B2 (ja) * | 1993-01-27 | 2001-03-05 | ポーラ化成工業株式会社 | メラニン産生抑制剤及び皮膚外用剤 |
CA2397198C (en) | 2000-03-06 | 2011-06-21 | Unilever Plc | Echinacea extract as anti-irritant and anti-aging booster in cosmetic compositions |
US7431939B1 (en) * | 2000-09-28 | 2008-10-07 | Mississippi State University | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
EP1570839B1 (en) | 2002-11-07 | 2008-07-09 | Kosé Corporation | Composition for preparation for external use on skin and method of using the same |
ITMI20032286A1 (it) * | 2003-11-24 | 2005-05-25 | Indena Spa | Composizioni per il trattamento di dermatiti atopiche di stati allergici cutanei e dell'acne |
US7226623B2 (en) * | 2005-10-31 | 2007-06-05 | Rutgers, The State University Of New Jersey | In vitro and in vivo anti-inflammatory effects of a sesquiterpene lactone extract from chicory (Cichorium intybus L.) |
FR2892923B1 (fr) | 2005-11-08 | 2009-01-16 | Engelhard Lyon Sa | Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques. |
JP2007300869A (ja) * | 2006-05-12 | 2007-11-22 | Kanehide Bio Kk | 高機能性健康食品、及び高機能性健康食品の製造方法 |
FR2904935A1 (fr) * | 2006-08-18 | 2008-02-22 | Centre Nat Rech Scient | Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant). |
JP2008231002A (ja) * | 2007-03-19 | 2008-10-02 | Ina Food Ind Co Ltd | 抗酸化剤及びラジカル消去活性化剤、並びにそれらいずれかが含まれた食品 |
EP2210505A1 (en) * | 2009-01-27 | 2010-07-28 | Nestec S.A. | Composition comprising caftaric acid and/or derivatives thereof |
-
2011
- 2011-06-28 SG SG10201505158UA patent/SG10201505158UA/en unknown
- 2011-06-28 ES ES11730933T patent/ES2741424T3/es active Active
- 2011-06-28 CA CA2803522A patent/CA2803522C/en not_active Expired - Fee Related
- 2011-06-28 CN CN201180030927.4A patent/CN102958501B/zh not_active Expired - Fee Related
- 2011-06-28 RU RU2012155852/15A patent/RU2012155852A/ru not_active Application Discontinuation
- 2011-06-28 BR BR112012032877-8A patent/BR112012032877B1/pt not_active IP Right Cessation
- 2011-06-28 KR KR1020127033430A patent/KR20130097090A/ko active Search and Examination
- 2011-06-28 EP EP11730933.6A patent/EP2588071B1/en not_active Not-in-force
- 2011-06-28 MX MX2012015235A patent/MX2012015235A/es unknown
- 2011-06-28 WO PCT/EP2011/060759 patent/WO2012000954A1/en active Application Filing
- 2011-06-28 SG SG2012094801A patent/SG186448A1/en unknown
- 2011-06-28 JP JP2013517237A patent/JP2013530995A/ja active Pending
- 2011-06-28 US US13/805,872 patent/US9491962B2/en active Active
- 2011-06-28 WO PCT/EP2011/060765 patent/WO2012000960A1/en active Application Filing
- 2011-06-28 CN CN201180030692.9A patent/CN103025307B/zh not_active Expired - Fee Related
-
2012
- 2012-12-20 CL CL2012003624A patent/CL2012003624A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040170581A1 (en) * | 2001-05-21 | 2004-09-02 | Florence Henry | Cosmetic agents |
JP2005194246A (ja) * | 2004-01-09 | 2005-07-21 | Ichimaru Pharcos Co Ltd | NF−κB活性化抑制剤 |
CN102333455A (zh) * | 2009-01-27 | 2012-01-25 | 雀巢产品技术援助有限公司 | 包含菊苣酸和/或其衍生物的组合物 |
Non-Patent Citations (1)
Title |
---|
王康才等: "紫锥菊属植物的化学成分、药理及开发利用研究进展", 《中药材》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666518A (zh) * | 2013-11-27 | 2015-06-03 | 瑞帝安有限公司 | 含有菊苣及枸桔的提取物的皮肤屏障强化用组合物 |
Also Published As
Publication number | Publication date |
---|---|
JP2013530995A (ja) | 2013-08-01 |
BR112012032877B1 (pt) | 2018-11-13 |
RU2012155852A (ru) | 2014-06-27 |
EP2588071B1 (en) | 2019-05-22 |
WO2012000954A1 (en) | 2012-01-05 |
CN103025307B (zh) | 2017-03-29 |
CN102958501B (zh) | 2016-10-26 |
CN102958501A (zh) | 2013-03-06 |
SG10201505158UA (en) | 2015-08-28 |
EP2588071A1 (en) | 2013-05-08 |
CA2803522C (en) | 2019-08-20 |
BR112012032877A2 (pt) | 2017-11-28 |
SG186448A1 (en) | 2013-01-30 |
WO2012000960A1 (en) | 2012-01-05 |
US9491962B2 (en) | 2016-11-15 |
CA2803522A1 (en) | 2012-01-05 |
CL2012003624A1 (es) | 2013-06-07 |
MX2012015235A (es) | 2013-02-15 |
ES2741424T3 (es) | 2020-02-11 |
KR20130097090A (ko) | 2013-09-02 |
US20130095070A1 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103025307B (zh) | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 | |
CN103517699B (zh) | 烘焙咖啡豆用于调节皮肤色素沉着的用途 | |
CN103025309B (zh) | 菊苣酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 | |
CN103079525A (zh) | 生咖啡豆用于调节皮肤色素沉着病症的用途 | |
CN103025308B (zh) | 咖啡酰酒石酸及衍生物在食品补充剂中用于调节皮肤色素沉着的用途 | |
CN103068360B (zh) | 烘焙咖啡豆和生咖啡豆的混合物用于调节皮肤色素沉着的用途 | |
KR102024628B1 (ko) | 발아콩 추출물을 포함하는 미백용 또는 탈모 방지용 조성물 | |
CN102985058B (zh) | 咖啡酰酒石酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 | |
CN103068359A (zh) | 生咖啡和益生菌用于调节皮肤色素沉着的用途 | |
CN102958500B (zh) | 咖啡酰酒石酸及衍生物在食品或饮料中用于调节皮肤色素沉着的用途 | |
JP2013256448A (ja) | 美白剤 | |
KR20170141973A (ko) | 금강송 발효물을 유효성분으로 포함하는 피부 미백용 조성물 | |
CN111728902A (zh) | 一种具有祛斑美白功效的组合提取物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200228 Address after: Vevey Co-patentee after: L'OREAL Patentee after: Societe des Produits Nestle S.A. Address before: Vevey Co-patentee before: L'OREAL Patentee before: NESTEC S.A. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170329 Termination date: 20210628 |